Follow The Filings

RCKT Rocket Pharmaceuticals Inc.

Health Care, filed as ROCKET PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 0.3%
  • $17M
  • 1 add 1 small

In 2026 Q2 Lee Ainslie added to Rocket Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 0.31%
  2. Lee Ainslie Add 0.12%

Who owns RCKT

Sorted by value, long equity only, as of 2026 Q2.

History
Lee Ainslie, Maverick Capital 0.12% Add +10.0% 3,923,963 $13M History
James Silverman, Opaleye Management 0.31% Small add +4.7% 1,000,000 $3.4M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RCKT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RCKT insider trades
  • $34K bought by 1 insider
  • $34K sold by 4 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Elisabeth Bjork Director
    Buy
    $34K 10,000 shares at $3.44 +25% to stake
    Traded Jan 2 Filed Jan 6
    ↗
  2. John Militello See Remarks
    Sale
    $3,240 1,086 shares at $2.98 1.6% of stake
    Traded Nov 18, 2025 Filed Nov 20, 2025
    ↗
  3. Jonathan David Schwartz See Remarks
    Sale
    $7,592 2,545 shares at $2.98 0.8% of stake
    Traded Nov 18, 2025 Filed Nov 20, 2025
    ↗
  4. Gaurav Shah CEO
    Sale
    $19K 6,276 shares at $2.98 0.8% of stake
    Traded Nov 18, 2025 Filed Nov 20, 2025
    ↗
  5. Martin Wilson General Counsel
    Sale
    $4,910 1,646 shares at $2.98 0.4% of stake
    Traded Nov 18, 2025 Filed Nov 20, 2025
    ↗
  6. John Militello See Remarks
    Sale
    $115K 28,918 shares at $3.96 30% of stake
    Traded Oct 14, 2025 Filed Oct 16, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 sales to cover taxes, 14 stock grants, 1 other transaction, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 1.01,2.03,3.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02 Filing Doc
8-K 2.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.00 $0.00 $0.00
Net income -$245.6M -$258.75M -$223.12M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $378.22M $378.18M $192.73M
Total non-current assets * $188.12M $149.52M $137.72M
Total assets $566.34M $527.7M $330.45M
Total current liabilities $48.5M $40.68M $30.21M
Total non-current liabilities * $25.26M $23.78M $23.02M
Total equity $492.57M $463.23M $277.22M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$194.92M -$209.72M -$190.01M
Cash from investing -$98.07M $131.71M $103.77M
Cash from financing $208.4M $185.74M $0.148M
Net change in cash * -$84.58M $107.72M -$86.1M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.